ABIVAX Announces $90M Agreement to Repurchase Royalty Certificates
ABIVAX (NASDAQ: ABVX) announced a $90 million agreement to repurchase and cancel all royalty certificates issued in September 2022. The transaction will be funded with $45 million cash and the issuance of approximately 403,347 ordinary shares at $111.57 per ADS. This move is intended to simplify ABIVAX's capital structure ahead of future commercialization efforts.
Tickers: $ABVX
Topics: capital structure royalty certificates share issuance